1. Home
  2. HURA vs SORA Comparison

HURA vs SORA Comparison

Compare HURA & SORA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • SORA
  • Stock Information
  • Founded
  • HURA 2009
  • SORA 2001
  • Country
  • HURA United States
  • SORA Hong Kong
  • Employees
  • HURA N/A
  • SORA N/A
  • Industry
  • HURA
  • SORA Other Specialty Stores
  • Sector
  • HURA
  • SORA Industrials
  • Exchange
  • HURA Nasdaq
  • SORA Nasdaq
  • Market Cap
  • HURA 131.8M
  • SORA 111.9M
  • IPO Year
  • HURA N/A
  • SORA 2025
  • Fundamental
  • Price
  • HURA $2.29
  • SORA $5.51
  • Analyst Decision
  • HURA Strong Buy
  • SORA
  • Analyst Count
  • HURA 2
  • SORA 0
  • Target Price
  • HURA $11.50
  • SORA N/A
  • AVG Volume (30 Days)
  • HURA 181.8K
  • SORA 29.0K
  • Earning Date
  • HURA 11-13-2025
  • SORA 01-01-0001
  • Dividend Yield
  • HURA N/A
  • SORA N/A
  • EPS Growth
  • HURA N/A
  • SORA N/A
  • EPS
  • HURA N/A
  • SORA N/A
  • Revenue
  • HURA N/A
  • SORA $17,619,363.00
  • Revenue This Year
  • HURA N/A
  • SORA N/A
  • Revenue Next Year
  • HURA N/A
  • SORA N/A
  • P/E Ratio
  • HURA N/A
  • SORA N/A
  • Revenue Growth
  • HURA N/A
  • SORA N/A
  • 52 Week Low
  • HURA $1.80
  • SORA $3.19
  • 52 Week High
  • HURA $7.20
  • SORA $14.15
  • Technical
  • Relative Strength Index (RSI)
  • HURA 39.99
  • SORA N/A
  • Support Level
  • HURA $2.16
  • SORA N/A
  • Resistance Level
  • HURA $2.61
  • SORA N/A
  • Average True Range (ATR)
  • HURA 0.13
  • SORA 0.00
  • MACD
  • HURA -0.02
  • SORA 0.00
  • Stochastic Oscillator
  • HURA 25.51
  • SORA 0.00

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About SORA Top Win International Limited Ordinary Shares

AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.

Share on Social Networks: